Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Pluristem Therapeutics Inc is a biotechnology business based in the US. Pluristem Therapeutics shares (PSTI) are listed on the NASDAQ and all prices are listed in US Dollars. Pluristem Therapeutics employs 146 staff and has a trailing 12-month revenue of around USD$23,000.
|Latest market close||USD$5.93|
|52-week range||USD$2.82 - USD$13.29|
|50-day moving average||USD$9.4829|
|200-day moving average||USD$9.3419|
|Wall St. target price||USD$9.6|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.863|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-11)||N/A|
|1 month (2020-12-22)||-12.28%|
|3 months (2020-10-18)||N/A|
|6 months (2020-07-18)||N/A|
|1 year (2020-01-18)||N/A|
|2 years (2019-01-18)||N/A|
|3 years (2018-01-18)||N/A|
|5 years (2016-01-18)||N/A|
|Gross profit TTM||USD$23,000|
|Return on assets TTM||-44.81%|
|Return on equity TTM||-91.77%|
|Market capitalisation||USD$152 million|
TTM: trailing 12 months
There are currently 1.2 million Pluristem Therapeutics shares held short by investors – that's known as Pluristem Therapeutics's "short interest". This figure is 1.8% down from 1.2 million last month.
There are a few different ways that this level of interest in shorting Pluristem Therapeutics shares can be evaluated.
Pluristem Therapeutics's "short interest ratio" (SIR) is the quantity of Pluristem Therapeutics shares currently shorted divided by the average quantity of Pluristem Therapeutics shares traded daily (recently around 212369.8943662). Pluristem Therapeutics's SIR currently stands at 5.68. In other words for every 100,000 Pluristem Therapeutics shares traded daily on the market, roughly 5680 shares are currently held short.
However Pluristem Therapeutics's short interest can also be evaluated against the total number of Pluristem Therapeutics shares, or, against the total number of tradable Pluristem Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Pluristem Therapeutics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Pluristem Therapeutics shares in existence, roughly 50 shares are currently held short) or 0.0601% of the tradable shares (for every 100,000 tradable Pluristem Therapeutics shares, roughly 60 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Pluristem Therapeutics.
Find out more about how you can short Pluristem Therapeutics stock.
We're not expecting Pluristem Therapeutics to pay a dividend over the next 12 months.
Pluristem Therapeutics's shares were split on a 1:10 basis on 25 July 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Pluristem Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Pluristem Therapeutics shares which in turn could have impacted Pluristem Therapeutics's share price.
Over the last 12 months, Pluristem Therapeutics's shares have ranged in value from as little as $2.82 up to $13.29. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Pluristem Therapeutics's is 2.6546. This would suggest that Pluristem Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients unsuitable for revascularization, recovery after surgery for hip fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of ARS. The company has a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermittent claudication; and nTRACK, a collaborative project with Leitat to examine gold nano particles labeling of stem cells. It also has collaboration agreements with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions; and BIH Center for Regenerative Therapy and Berlin Center for Advanced Therapies to expand its framework and research agreement, as well as conduct a joint project evaluating the therapeutic effects of the registrant's patented PLX cell product candidates for treatment of the respiratory and inflammatory complications associated with the COVID-19 coronavirus. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.